MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 28981-28990 Newer>
The Motley Fool
February 29, 2008
David Lee Smith
McClatchy's McWeak Quarter With its revenues and its share price in retreat, newspaper publisher McClatchy has taken a big hit. mark for My Articles 97 similar articles
The Motley Fool
February 29, 2008
Anders Bylund
Dell Is Building a Global Comeback Dell is sidestepping the slow domestic economy by growing at breakneck speed abroad. mark for My Articles 951 similar articles
The Motley Fool
February 29, 2008
Anders Bylund
End of the Line, New Line Time Warner's absorption of New Line studio could signal other big changes ahead. mark for My Articles 308 similar articles
The Motley Fool
February 29, 2008
Rich Duprey
Brown-Forman Gets Plastered The wine and spirits distributor stumbles in the latest quarter on rising costs and falling volumes. mark for My Articles 120 similar articles
The Motley Fool
February 29, 2008
David Lee Smith
Alcoa and a Tale of Intrigue In a lawsuit that could be the stuff of a riveting global business novel, a Bahrain-based company accuses Alcoa of bribing officials and inflating prices of alumina. mark for My Articles 190 similar articles
The Motley Fool
February 29, 2008
Brian Orelli
RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease? mark for My Articles 75 similar articles
The Motley Fool
February 29, 2008
Toby Shute
Drilling With Pride Offshore driller Pride International nearly doubled its per-share earnings compared to the prior year, but looking forward, 2008 may not have the same potential. mark for My Articles 388 similar articles
The Motley Fool
February 29, 2008
Brian Orelli
Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years. mark for My Articles 808 similar articles
The Motley Fool
February 29, 2008
Brian Lawler
FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder. mark for My Articles 306 similar articles
The Motley Fool
February 29, 2008
Rick Aristotle Munarriz
Microsoft Sees Google's Point With Google Sites, the search leader takes another swing at Microsoft. mark for My Articles 2167 similar articles
<Older 28981-28990 Newer>    Return to current articles.